Form 4: ONCY VP Buys 10,000 Shares Under 10b5-1 Plan

Oncolytics Biotech Inc.'s VP of Product Development, Allison Hagerman, purchased 10,000 common shares at $0.8298 each, increasing her direct beneficial ownership to 115,059 shares.

Summary

• Allison Hagerman, VP, Product Development at Oncolytics Biotech Inc. (ONCY), acquired common shares.
• The transaction involved the purchase of 10,000 common shares.
• The shares were acquired at a price of $0.8298 per share.
• Following this transaction, Ms. Hagerman directly beneficially owns 115,059 common shares.
• The transaction occurred on February 12, 2026.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading schedule.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an executive is increasing their stake, demonstrating confidence. The Rule 10b5-1 plan suggests it's a scheduled purchase rather than an opportunistic one, tempering the immediate bullish signal slightly.

Positives

• An insider, the VP of Product Development, purchased 10,000 common shares, which can signal confidence in the company's future prospects.
• The purchase increases the executive's direct beneficial ownership, further aligning her interests with those of shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider purchases, especially by key executives like a VP of Product Development, can signal management's belief in the company's future, potentially driven by upcoming product milestones or positive clinical trial data in the biotech sector. This contrasts with general market sentiment which might be more volatile.

Comparison to Industry Standards

• Insider buying activity is generally viewed positively across industries, as it aligns management's interests with shareholders.
• While the dollar amount of this specific transaction ($8,298) is modest compared to large institutional buys, it represents a direct investment by a key executive.
• For example, similar insider purchases in other biotech firms, even if small in absolute terms, are often interpreted as a vote of confidence in their respective pipelines or strategic direction.

Related Party Transactions

• Allison Hagerman, VP of Product Development, purchased 10,000 common shares of Oncolytics Biotech Inc. (ONCY) at $0.8298 per share, which is considered an insider transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign of management confidence in the company's future performance.
• Employees may see this as a positive indicator of the company's stability and growth prospects.

Key Dates

Recommendation

While insider buying is generally a positive indicator of management confidence, this specific transaction, executed under a Rule 10b5-1 plan, suggests a pre-scheduled purchase rather than an opportunistic one based on immediate, non-public information. The relatively modest size of the purchase ($8,298) also limits its impact as a strong 'buy' signal. Investors should 'hold' and monitor for further developments or larger, discretionary insider purchases.

Keywords

Oncolytics Biotech Inc., ONCY, Insider Trading, Form 4, Share Purchase, Allison Hagerman, Biotech, Executive Stock Purchase, Rule 10b5-1